27 results

• FDA Issues Additional Tazverik Blood Cancer Warnings After Market Recall

  May 15, 2026

  Irvin Jackson

  Federal regulators have concluded that Tazverik blood cancer rates make the lymphoma drug a bigger risk to patients' health than its benefits, urging providers to stop its use immediately.

• Link Between Dupixent and Cancer Withheld From Doctors and Users, Lawsuit Alleges

  May 11, 2026

  Michael Adams

  A lawsuit alleges an Illinois woman developed CTCL after using Dupixent, raising concerns the manufacturer may have withheld concerns that the drug could contribute to cancer.

• Tazverik Removed From Market Due to Cancer Concerns

  March 11, 2026

  Irvin Jackson

  Ipsen is removing its lymphoma drug Tazverik from the market due to increased cancer risks just six years after being granted accelerated approval by the FDA.

• Port Catheter Blood Clot Results in Lawsuit Against Device Manufacturer

  February 4, 2026

  Irvin Jackson

  AngioDynamics is facing a growing number of port catheter lawsuits, including a claim filed by an Arizona woman who alleges that her Vortex port was defectively designed, causing a blood clot that required the device to be removed.

• Tattoo Ink Side Effects Linked to Inflammation, Immune-Cell Death: Study

  December 5, 2025

  Martha Garcia

  Swiss researchers warn that tattoo ink can accumulate in the lymph nodes for months or even permanently, potentially disrupting immune system function.

• Dupixent Cancer Risks Outlined in User Stories, as Evidence Mounts of T-Cell Lymphoma Link

  October 8, 2025

  Russell Maas

  Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.

• Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks

  August 26, 2025

  Irvin Jackson

  Recent studies warn that the eczema treatment Dupixent appears to significantly increase the risk of cutaneous T-cell lymphoma (CTCL).

• Study Finds Individuals With Tattoos Face Increased Lymphoma Risks

  May 31, 2024

  Grace Muller

  A new study warns that people with tattoos face an increased risk of lymphoma, potentially due to ink particles traveling to lymph nodes.

• Ukoniq Side Effects Linked to Increased Risk of Death, FDA Warns, Withdraws Drug Approval

  June 3, 2022

  Irvin Jackson

  The FDA has withdrawn approval for the lymphoma drug Ukoniq after determining the risk of death outweighs any potential benefits.

• Ukoniq FDA Warning Issued Over Increased Risk of Death with Cancer Drug

  February 4, 2022

  Irvin Jackson

  The FDA warns that the relatively new cancer drug, Ukoniq, may increase the risk of death in the lymphoma patients it was designed to treat.